Erik Nordkamp – Managing Director, Pfizer UK
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Pfizer has a rich heritage of working within the UK since our first facility was opened back in 1952.
Over the past 69 years, we have continued to invest in the UK and are committed to working with the NHS and other healthcare organisations across the industry developing solutions to improve the delivery of care and patient outcomes.
We support the NHS Long Term Plan‘s ambition for prevention, empowering people to control their own health, harnessing new technologies and improving the quality of patient care and health outcomes. We believe these are key to help ensure a sustainable NHS and gives the government, the NHS and the pharmaceutical industry the chance to form a new relationship, truly working together to meet these challenges head-on while putting patients first.
In 2020, we spent over £295 million supporting research and development carried out in the UK and contributed to 126 collaborations with universities, pharmaceutical companies, industries and others. Through collaborations with scientists, academics and clinicians, sharing knowledge, skills and expertise we aim to improve the health and lives of people in the UK and around the world. During 2020, we had 36 clinical trials on-going in the UK, across 69 UK sites, involving over 977 patients since the trials started.
The company provides medicines to help treat a variety of serious and life–threatening conditions. With the combined portfolios and resources of Wyeth and Pfizer, Specialty Care has grown substantially. The business unit’s current portfolio includes more than 20 medicines in 12 disease areas, and the pipeline contains more than 25 compounds and indications in Phases II and III. Specialty Care holds leadership positions in vaccines and disease areas such as inflammation, infectious disease, hemophilia and ophthalmology. Neuroscience, Gastroenterology, Women’s Health, Infectious Diseases and Immunology.
Prescription medicines (top 50): Lipitor (1), Lyrica (15), Viagra (26), Xalatan (36).
Contact:
Headquarters: Walton Oaks, Dorking Rd, Tadworth KT20 7NS, Reino Unido
Tel: +44 (0)1304 616161, 0345 608 8866
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Pfizer holds a prominent position in Portugal’s pharmaceutical landscape, especially in the hospital business and for COVID-19-related products, with the emphasis now on sustainable growth post-COVID. Paulo Teixeira, a 26-year…
Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma…
India’s pharma industry has big dreams. At the recent Annual Summit of Organisation of Pharmaceutical Producers of India (OPPI) the nation’s policymakers, academicians, industry leaders, innovators, and scientists gathered to…
Morocco is undergoing ambitious reforms, extending universal healthcare coverage to all its citizens while resolving the shortcomings laid bare during the COVID-19 pandemic. Endorsed by a USD 450 million Program-for-Results…
Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps…
As North Africa cluster lead Pfizer veteran Diego Forero heads up Morocco, Tunisia, Libya, and Algeria in addition to being the country manager for Morocco. He describes the company’s 57-year…
The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear novel. In fact, the pioneers whose discoveries enabled the…
Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time…
See our Cookie Privacy Policy Here